The major concern in the therapeutic administration of coreceptor inhibitors is the possibility that resistance will manifest by a change in coreceptor tropism from CCR5 to CXCR4, or that an outgrowth of an X4-tropic virus subset will come to dominate the intrapatient virus population.
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}